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It is well known that luteinizing hormone (LH), like many
other glycoproteins, is heterogeneous and presents several
circulating isoforms. Recently, new sensitive immunometric
assays measuring intact LH were developed. These assays
have been found to underestimate or to be incapable of
recognizing LH in some patients. This study was undertaken
to determine the prevalence of such cases and to define their
clinical characteristics. We compared three LH assays using
as capture antibodies either a monoclonal antibody that reacts
exclusively with intact LH (ES 600 Boehringer, Stratus
Baxter) or a monoclonal antibody against the 0 subunit of
LH (IMX Abbott). In 17% of 90 patients tested, ES 600
measured > 50% lower LH concentrations when compared
with the IMX. Moreover, in two cases LH was not detectable
by ES 600 or Stratus, whereas it was normal with the IMX.
We found another five such cases and discuss here the clinical
data and results of different hormone measurements in these
seven cases of 'invisible LH'. Although bioactive LH (mouse
Leydig cell assay) was normal, the existence of low or even
undetectable LH was clinically confusing and led to expensive
complementary investigations such as gonadotrophin-
releasing hormone analogue tests and magnetic resonance
imaging. The uses and limitations of these assays are
illustrated by different clinical situations in which the results
of the different assays have been misleading.
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Introduction
Luteinizing hormone (LH) is a glycoprotein hormone which
consists of two non-covalently linked subunits. The a subunit
is common to other pituitary glycoproteins such as follicle-
stimulating hormone (FSH) and thyroid-stimulating hormone
(TSH). The /3 subunit carries the specificities of the biological
effects of LH. Both subunits are glycosylated at specific residues
and the degree of glycosylation modulates the biological activity
of LH. Glycosylation is heterogeneous and leads to many different
circulating variants of LH (Jeffcoate, 1993). After isoelectric
focusing, seven different isoforms of LH have been identified
(Weise et al., 1983). The more acidic isoforms have a longer
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half-life and display lower receptor binding and in-vitro
bioactivity as compared with the more basic isohormones.
The specificity of an immunoassay is dependent"upon the
epitope recognized by the antibodies used in the assay. For the
glycoprotein hormones, recognized epitopes are either amino
acids or oligosaccharide structures. Classic radioimmunoassays
for LH used polyclonal antibodies composed of immunoglobulins
recognizing most if not all circulating forms of LH. Recently,
new sensitive immunometric assays have been developed. These
are based on two monoclonal antibodies recognizing different
epitopes on the LH molecule (sandwich technique) These assays
have improved sensitivity and specificity (Apter et al., 1989;
Jaakkola et al., 1990). However, Pettersson and Soderholm,
(1991) by comparing two of these LH assays, observed major
discrepancies in LH concentrations in about one quarter of a
randomly selected population. Moreover, in five cases LH was
not recognized at all by certain antibodies.
The aim of this study is to assess the prevalence of 'partially
visible' and 'invisible' LH in our population and to discuss the
clinical implications of these findings.
Materials and methods
A total of 90 consecutive patients needing an LH determination
between August and December 1993 were included in the
prevalence study. These included 17 males consulting for
impotence or sterility, 26 women consulting for menopausal
complaints, 21 women with infertility, 14 women with
spaniomenorrhoea (including polycystic ovary syndrome), nine
women with suspected hypothalamic amenorrhoea and three with
galactorrhoea. Serum samples were obtained and analysed by
two different types of assay. Assay 1 was an immunoenzymo-
metric assay (IEMA) using a monoclonal antibody recognizing
an epitope on the a/3 dimer of intact LH as the capture antibody
and a monoclonal anti-jS subunit as the detection antibody (ES
IMXLH Boehringer
ES600
Stratus LH
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Fig. 1. Schematic representation of luteinizing hormone (LH) assay
constructs.
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600; Boehringer, Mannheim, Germany; Figure 1). Assay 2 was
a microparticle enzyme immunoassay (MEIA) using a
monoclonal anti-/3 subunit as the capture antibody and a
polyclonal anti-human LH as the detection antibody (IMX;
Abbott, Chamonix, Switzerland; Figure 1). The detection limit
of both assays was 0.5 mlU/ml.
Sera from seven patients with LH values undetectable by ES
600 and Stratus were obtained from the practice of two private
r2-0.966
all data r2=0.642
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Fig. 2. Correlation between luteinizing hormone (LH) values
determined by IMX and ES 600. Correlation coefficient
r
2
 = 0.642 for all data, and 0.966 when 18 pairs of values in
which LH as measured by ES600 was 50% lower than that found
in IMX.
endocrinologists and from our own patients. These sera remained
frozen (-20°C) for up to 2 years before being re-assayed. The
concentration of LH in these samples was measured by the two
assays described above and with an IEMA using two monoclonal
antibodies directed against intact LH as capture and detection
antibodies (Stratus; Baxter, Dudingen, Switzerland; detection
limit 0.5 mlU/ml; Figure 1). FSH and oestradiol were also
measured in these samples by Stratus (Baxter) and Vidas
(Biomerieux, Geneve, Switzerland) respectively. Finally, in five
out of seven samples bioactive LH was also determined by the
mouse Leydig assay as described by Dufau et al. (1974).
Results
LH values obtained by ES 600 and IMX assays for the 90
consecutive samples are shown in Figure 2. The correlation
coefficient (r2 = 0.642) was significantly different from zero
(P < 0.0001). By eliminating 18 pairs of values for which the
concentration of LH as measured by ES 600 was 50% lower than
the corresponding value found with IMX, the correlation
coefficient increased to 0.966. Among these 18 samples, two had
undetectable LH on the ES 600 assay whereas readings of 2.4
and 1.3 IU/1 were obtained with the IMX assay. Thus 'partially
visible LH' (values 50% lower with ES 600 than with IMX) were
observed in 17.8% (16/90) of the samples and 'invisible LH'
(values undetectable with ES 600 assay but detectable with IMX
assay) were observed in 2.2% (2/90) of our samples. Similar
values with both assays were observed for 80% of the samples.
Table I. Hormone
Patient age
and sex
Case 1: 48, F
Case 2: 44, F
Daughter, 23
Son, 20
Case 3: 40. F
Case 4: 32, F
Case 5: 41. F
Case 6: 51, M
Case 7: 37, M
measurements in the
History and
complaints
RP. hot flushes
RP. hot flushes
RP, pre-menstrual
syndrome
PCO, post-pill
amenorrhoea
Mother, 68
RP, primary
infertility
impotence
infertility
seven cases with 'invisible LH'
LH measurements (IU/1)
IMX
59
1
i
234
47
7
1
18
10
5
ND
24.6
ND
18.2
37
ND
15.2"
26"
157.3"
4
25
ND
8.5
Stratus
i
i
< i
I
< l
3.5
2.6
<
<
<
<
7
<
<
<
1
< 1
3.8
ES600
<1
ND
< i
< '
ND
ND
ND
< !
<1
< 1
< i
6
ND
< l
< i
< '
ND
ND
< l
ND
Bioactive
41
ND
85
26
1
58
ND
ND
ND
66
ND
ND
ND
ND
ND
ND
ND
25
32
ND
41
FSH
- (IU/1)
59
ND
57
ND
ND
ND
8.4
9.3
6.2
10
65
7
ND
ND
ND
4.6
ND
19
ND
Oestradiol
(pmol/1)
60
ND
80
ND
ND
ND
100
1351
112
303
ND
772
2739
3697
3877
Testosterone
(nmol/1)
8.4
ND
10.4
ND
RP = regular periods: PCO = polycystic ovary disease: ND = not determined: F = female; M = male; I = 30 min after GnRH.
"After clomid.
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Invisible LH
The two samples with 'invisible LH' plus another five samples
from other subjects were analysed in greater detail. The samples
came from five women and two men. Four of the five women
(cases 1,2,3 and 5, Table I) had an uncomplicated history with
regular cycles; one had a spaniomenorrhoea due to polycystic
ovary syndrome. They consulted for hot flushes (n = 2), pre-
menstrual syndrome (n = 1), post-pill amenorrhoea (n = 1) or
primary infertility (n = 1). The two men consulted for impotence
or infertility (Table I). In all seven cases LH concentrations
measured by Stratus and/or ES 600 were undetectable, whereas
the concentrations of LH as measured by IMX or bioassay where
either normal or increased (Table I). In two women and one man
(cases 1, 2 and 6), 100 /*g of gonadotrophin-releasing hormone
(GnRH) induced an increase in bioactive- and IMX-measured
LH, whereas LH measured in the same samples by Stratus
remained undetectable. In one patient (case 5, Table I),
clomiphene citrate was given to induce ovulation and LH
measured daily on three consecutive days; serum LH
concentrations were undetectable with Stratus or ES 600 but were
measurable with IMX. LH measurements were also performed
in the children of patient 2 and in the mother of patient 4. In
these relatives, Stratus gave lower LH values than IMX.
Discussion
The lack of recognition or partial recognition of circulating LH
has been known for some time. During GnRH agonist or
antagonist therapy, several authors (Bhasin and Swerdeloff, 1986;
Lahlou et al, 1987; Bischof and Herrmann, 1988) observed
discrepancies between different LH immunoassays. One month
after GnRH treatment, LH concentrations as measured by
polyclonal radioimmunoassays were not different from pre-
treatment values, whereas LH concentrations measured by
radioimmunometric assays or by bioassays were very low or even
undetectable. This was explained by the fact that circulating free
a subunits recognized by polyclonal antibodies are significantly
increased by GnRH treatment, whereas /3 subunits specifically
recognized by most monoclonal antibodies are decreased to
undetectable amounts (Meldrum et al., 1984). It was therefore
considered that under those circumstances, polyclonal
radioimmunoassays tend to overestimate LH.
Among the 90 patients in whom we measured LH by two
different assays, 17.8% of them had ES 600 LH values (only
intact LH) which were 50% smaller than IMX LH values (only
13 subunit). Restricted reactivity against monoclonal antibodies
that react exclusively with intact LH was reported for the first
time by Pettersson and Soderholm (1991) in 25% of 244 samples
tested with 11 different antibodies. In a later study from the same
group (Pettersson et al., 1991) a similar observation was
described in 19 out of 83 patients (22.9%). Gervasi et al. (1991)
also observed important discrepancies between three
commercially available LH kits in -20% of 155 samples. Our
present observations confirm and extend these previous reports.
These cases of 'partially visible LH' are frequent (17 — 25%).
From a clinical point of view underestimation of LH can impair
the detection of the ovulatory LH peak (e.g. case 5) or artificially
decrease the LH/FSH ratio leading to non-recognition of
polycystic ovarian disorder (PCOD) (e.g. case 4). 'Invisible LH'
is much less frequent (~2%) and is clinically speaking more
easily recognized.
In our seven patients with 'invisible LH', the two assays using
monoclonal antibodies and recognizing intact LH as capture
antibodies (Stratus and ES 600) did not recognize LH in the serum
samples, whereas the assay using a capture antibody to the /3
subunit (IMX) measured normal or increased concentrations of
LH. Although gonadotrophins were measured for clinical
reasons, these patients with 'invisible LH' did not seem to have
a specific clinical profile.
Low LH can be observed in certain cases of secondary
amenorrhoea, such as anorexia nervosa, human chorionic
gonadotrophin (HCG) producing tumours, hypogonadotrophic
hypogonadism, or pregnancy. In these cases, however, FSH is
also low. None of our patients fell into any of these categories
since their FSH were either normal or increased. Because certain
cases of pituitary adenomas have been described with low LH
and normal FSH concentrations (Daneshdoost et al., 1991),
'invisible LH' as observed in our study can be confusing and
lead to unnecessary and expensive investigations such as magnetic
resonance imaging of the pituitary, as we performed in patients
2 and 7.
The inability to detect LH by monoclonal antibodies raised
against intact LH does not seem to be due to the non-recognition
of a particular isoform of LH (Gervasi et al., 1991).
Imse et al. (1992), using a bioassay and five different
immunoassays, studied LH pulsatility in the serum of women
suffering from PCOD. They observed that all pulses registered
by the bioassay were detectable by a conventional
radioimmunoassay (polyclonal antibodies) but some pulses were
not seen by certain monoclonal antibodies. These authors
suggested that conformational changes, occurring during post-
translational processing or exocytosis, modify the molecular
structure of LH in such a way that a particular epitope cannot
be recognized by highly specific monoclonal antibodies.
Similarly, gel filtration studies in one case of 'invisible LH' have
shown the presence of an LH species of lower molecular weight
than intact LH but heavier than its free /3 subunit. The authors
concluded that 'invisible LH' was due to the existence of a
fragmented form of LH where at least part of the 0 subunit was
lost (Pettersson et al., 1992). Since similar observations were
made with HCG leading to the discovery of nicked /3 HCG
(Puisieux et al., 1990; Bischof et al., 1994), we postulate that
the fragmented forms of LH could be nicked /3 LH.
Among our patients with invisible LH, the two children of
patient 2 and the mother of patient 4 had 'partially visible LH',
suggesting a genetic origin of these variant forms of LH. In the
patient studied by Pettersson et al. (1992), the mother had
undetectable LH and the concentrations found in the father and
three sisters were only 'partially visible'. As pointed out by the
authors, these observations suggest an autosomal dominant
inheritance of this (these) LH variant(s).
In conclusion we consider that the development of new
immunoassays for LH, based on monoclonal antibodies that
recognize specifically the intact LH and not its free /3 subunit,
have led to the discovery of some genetic variants of LH, which
are either partially recognized (17-25% of cases) or not
recognized at all (2% of cases). This report illustrates the potential
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clinical problems associated with 'invisible LH'. Discrepancies
between LH values on the one hand and FSH and sexual steroid
values on the other will frequently allow undetectable LH to be
questioned. However, in cases of 'partially visible LH' it is not
possible to guess which are the underestimated values. Therefore
we would recommend that either a polyclonal assay is used
directly (although this can overestimate LH in certain
circumstances) or that an assay which captures LH through its
/? subunit is used.
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